This is an open-label, non-randomized, biopsy-based mechanistic study on pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome.
This study aims at elucidating the mechanism of action of ianalumab in salivary glands and explore relationships with clinical assessments